Mydecine Innovations Group Valuation

Is MYIG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MYIG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MYIG's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MYIG's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MYIG?

Key metric: As MYIG is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for MYIG. This is calculated by dividing MYIG's market cap by their current book value.
What is MYIG's PB Ratio?
PB Ratio	-0.03x
Book	-CA$17.45m
Market Cap	CA$467.41k

MYIG key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-1x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does MYIG's PB Ratio compare to its peers?

The above table shows the PB ratio for MYIG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.1x
MAX Maxrets Ventures	17.5x	n/a	UK£332.8k
KNB Kanabo Group	1x	n/a	UK£6.0m
N4P N4 Pharma	1.9x	n/a	UK£2.4m
NFX Nuformix	0.1x	n/a	UK£479.3k
MYIG Mydecine Innovations Group	n/a	n/a	UK£333.5k

Price-To-Book vs Peers: MYIG has negative equity and a Price-To-Book Ratio (-0x) compared to the peer average (5.1x).

Price to Book Ratio vs Industry

How does MYIG's PB Ratio compare vs other companies in the GB Pharmaceuticals Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
EAH ECO Animal Health Group	0.6x	39.2%	US$61.94m
OCTP Oxford Cannabinoid Technologies Holdings	0.6x	15.1%	US$1.60m
NFX Nuformix	0.1x	n/a	US$608.54k

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: MYIG has negative equity and a Price-To-Book Ratio (-0x) compared to the European Pharmaceuticals industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is MYIG's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MYIG PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-0.03x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MYIG's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.2b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$742.70

-0.8%

-8.6%

hVIVO

UK£146.3m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

-1.1%

6.4%

Hikma Pharmaceuticals

UK£4.3b

Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

HIKL

UK£19.41

4.0%

12.9%